Atractylenolide III inhibits epithelial-mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2022.12614
Abstract: Compared with the available drugs for the treatment of fibrosis in other organs, the development of intestinal anti-fibrosis drugs is limited. Therefore, it is of practical significance to examine novel drugs to delay or block… read more here.
Keywords: mesenchymal transition; atl iii; atractylenolide iii; iii ... See more keywords
Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Biological Sciences"
DOI: 10.7150/ijbs.68873
Abstract: Background: Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver diseases worldwide. At present, there are no effective pharmacological therapies for NAFLD except lifestyle intervention-mediated weight loss. Atractylenolide III (ATL III),… read more here.
Keywords: atl iii; treatment; adiponectin receptor; fatty liver ... See more keywords